|
|
|
|
|
|
By Deborah Day Barbara, the Alliance for mRNA Medicines | mRNA medicines represent the genesis of a fourth pillar of pharma innovation. While exciting, there are several critical challenges we must solve to strengthen this pillar, including stability and deliverability. |
|
|
|
|
| Integrated Solutions For Advanced Therapies | White Paper | Catalent | The right CDMO offering integrated services can ease increasingly common CGT manufacturing problems such as scale, raw material access, viral vector production, and quality requirements. |
|
|
|
| Methods for mRNA Poly(A) Sizing | Poster | By Lauren Hinkel, Ryan Williams, Calleigh Herren, and Theresa Legan, Vernal Biosciences | This study used Oxford Nanopore Technologies' Direct RNA Sequencing Kit and obtained successful sizing of poly(A) tail regions. The results are presented in a histogram and table format. |
|
|
| A New Centre For Continuous mRNA Manufacturing | Article | ReciBioPharm | Explore how a partnership between academia, regulatory agencies, and manufacturing organizations has the potential to reshape the way we produce and distribute mRNA-based therapies. |
|
|
|
| Biotech Submits NDA After Risk-Based Mock Inspection | An emerging biotech company recently took a preventative approach to mitigate risks, identify potential concerns before an FDA inspection, and submit their NDA. See how these proactive measures accurately addressed gaps within its application and led to a successful submission. |
|
|
|
|
|
.png){kind=logo}
